Versant Capital Management’s Amneal Pharmaceuticals AMRX Stock Holding History

Versant Capital Management’s Portfolio AMRX Stock Details AMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$52.8K	Buy	2,624 +66	+3%	+$1.19K	﹤0.01%	1368
2026 Q2	$44.3K	Buy	2,558 +125	+5%	+$1.71K	﹤0.01%	1439
2026 Q1	$30.2K	Hold	2,433	–	–	﹤0.01%	1566
2025 Q4	$30.7K	Hold	2,433	–	–	﹤0.01%	1373
2025 Q3	$24.4K	Buy	2,433 +490	+25%	+$4.4K	﹤0.01%	1476
2025 Q2	$15.7K	Buy	+1,943	New	+$14.6K	﹤0.01%	1657
2022 Q2	–	Sell	-87	Closed	–	–	1432
2022 Q1	$0	Hold	87	–	–	﹤0.01%	1446
2021 Q4	$0	Hold	87	–	–	﹤0.01%	1425
2021 Q3	$0	Hold	87	–	–	﹤0.01%	1437
2021 Q2	$0	Hold	87	–	–	﹤0.01%	1431
2021 Q1	$1K	Hold	87	–	–	﹤0.01%	1311
2020 Q4	$0	Hold	87	–	–	﹤0.01%	1329
2020 Q3	$0	Hold	87	–	–	﹤0.01%	1289
2020 Q2	$0	Hold	87	–	–	﹤0.01%	1276
2020 Q1	$0	Hold	87	–	–	﹤0.01%	1292
2019 Q4	$0	Buy	+87	New	+$302	﹤0.01%	1343
2019 Q2	–	Sell	-19	Closed	–	–	1386
2019 Q1	$0	Sell	19 -1,115	-98%	-$14.7K	﹤0.01%	1544
2018 Q4	$15K	Hold	1,134	–	–	0.01%	643
2018 Q3	$25K	Buy	+1,134	New	+$23.9K	0.01%	524

Other funds holding AMRX

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $64.1B AUM 28.9% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Congress Asset Management Boston, Massachusetts $15.4B AUM 30.39% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Tucker Asset Management Littleton, Colorado $406M AUM 20.49% 1-Year Est. Return

Versant Capital Management's AMRX Position: Q3 2026 in Review

Versant Capital Management increased its Amneal Pharmaceuticals (AMRX) stake by 2.6% in Q3 2026, buying an estimated $1.19K and bringing the position to 2,624 shares worth $52.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1368.

Versant Capital Management first reported a position in AMRX in Q3 2018 and has held it in 19 quarters since. 156 funds tracked by Wall St. Rank hold AMRX as of Q3 2026.

Versant Capital Management held 2,624 shares of Amneal Pharmaceuticals worth $52.8K as of Q3 2026.
Versant Capital Management bought 66 Amneal Pharmaceuticals shares in Q3 2026, an estimated $1.19K.
Amneal Pharmaceuticals made up ﹤0.01% of Versant Capital Management's portfolio in Q3 2026, its #1368 holding.
Versant Capital Management first reported a position in Amneal Pharmaceuticals in Q3 2018 and has held it in 19 quarters since.
156 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q3 2026.

Based on Versant Capital Management's 13F filing for Q3 2026, filed 2 Oct 2026.